Pulse Biosciences (NASDAQ: PLSE) updates investor deck on nPulse programs

Rhea-AI Filing Summary

Pulse Biosciences, Inc. furnished a current report describing that on January 14, 2026 it posted an updated investor presentation on its website. The updated deck highlights recent progress in product development programs for its proprietary nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp and nPulse Cardiac Catheter. The company plans to use this presentation in meetings with investors, analysts and others, and has attached it as Exhibit 99.1 and made it available in the Investors section of its website. The information is provided under a Regulation FD disclosure item and is treated as “furnished,” not “filed,” which limits certain legal liabilities.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001625101 0001625101 2026-01-14 2026-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 14, 2026

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware	001-37744	46-5696597
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)
510-906-4600
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 14, 2025, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses recent progress in the Company’s ongoing product development programs relating to its proprietary nPulse Vybrance Percutaneous Electrode, its nPulse Cardiac Clamp, and its nPulse Cardiac Catheter. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”

Except for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of January 2026, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Investor Deck dated January 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PULSE BIOSCIENCES, INC.
Date: January 14, 2026	By:	/s/ Paul A. LaViolette
		Paul A. LaViolette
		Chief Executive Officer (Principal Executive Officer)

FAQ

What did Pulse Biosciences (PLSE) disclose in this 8-K?

Pulse Biosciences disclosed that it posted an updated investor presentation on January 14, 2026, describing recent progress in its nPulse product development programs.

Which products are highlighted in Pulse Biosciences' updated investor deck?

The updated investor deck covers ongoing development of the company’s nPulse Vybrance Percutaneous Electrode, its nPulse Cardiac Clamp and its nPulse Cardiac Catheter.

Where can investors access Pulse Biosciences' new investor presentation?

Investors can access the updated investor presentation as Exhibit 99.1 to the report and on Pulse Biosciences’ website at www.pulsebiosciences.com under the “Investors” section.

How will Pulse Biosciences use the updated investor presentation?

Pulse Biosciences expects to use the updated investor presentation, in whole or in part and possibly with modifications, in presentations to investors, analysts and others.

Is the Pulse Biosciences investor presentation considered filed with the SEC?

The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated into other SEC filings.

As of what date is the information in Pulse Biosciences' investor deck current?

The company states that the information in the investor deck is as of January 2026 and that it has no obligation to update it except as required by law.